Cystinuria Treatment Market: Penicillamine to Dominate Global Market
Cystinuria Treatment Market: Introduction
Cystinuria is a rare autosomal recessive metabolic disease causing defective transepithelial amino acid transport in the kidneys. Cystine dissolves and returns to the bloodstream after entering the kidneys. People with cystinuria have a genetic defect that interferes with this process. As a result, cystine builds up in urine and forms crystals or stones.
Request Brochure for Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=77191
Key Drivers and Restraints of Global Cystinuria Treatment Market
High demand for disease specific novel treatment is a major driver of the global cystinuria treatment market. Cystinuria is rare disease; however, pharmaceutical companies are continuously innovating new treatment methods and drug class for cystinuria treatment. In July 2019, Retrophin announced the FDA approval of THIOLA EC (tiopronin) 100mg and 300mg tablets for the treatment of cystinuria.
However, limited funding and operating revenue for research & development on targeted therapies for cystinuria hamper the growth of the global market.
Request for Analysis of COVID19 Impact on Cystinuria Treatment Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=77191
North America to Dominate Global Cystinuria Treatment Market
In terms of region, the global cystinuria treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
In terms of revenue, North America dominated the global cystinuria treatment market in 2019, followed by Europe. However, the market in Asia Pacific is likely to expand at a higher CAGR from 2020 to 2030.
Rise in cases of cystinuria, surge in use & awareness about cystinuria treatments and procedures, and technological advancements are the key factors boosting the growth of the cystinuria treatment market in North America
Cystinuria affects about 1 in 15,000 people in the U.S. Heterozygote carriers are about 1 in 170 people. It accounts for approximately 1% of all renal stones.
Key Players Operating in Global Cystinuria Treatment Market
The global cystinuria treatment market was highly fragmented in 2019. Key players operating in the global market are:
- Retrophin, Inc.
- Mission Pharmacal Company
- Revive Therapeutics Ltd.
- Teva Pharmaceutical Industries Ltd.
- Amerigen Pharmaceuticals Limited
- Mylan N.V.
- Bausch Health
- Zhejiang Huahai Pharmaceutical Co., Ltd.
Pre book Cystinuria Treatment Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=77191<ype=S
Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Mr. Rohit Bhisey
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453